Department of Pulmonary Medicine, STZ Center of Excellence for Asthma and COPD, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
Department of Science, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
J Asthma. 2023 Oct;60(10):1869-1876. doi: 10.1080/02770903.2023.2196563. Epub 2023 Apr 21.
Severe asthma is associated with a serious disease burden, partially caused by limitations in activity and work impairment.
This study aims to relate treatment with biologics targeting IL-5/5Ra to work productivity and activity in the long term in a real-world context.
This is a registry-based multi-center cohort study evaluating data from adults with severe eosinophilic asthma included in the Dutch Register of Adult Patients with Severe Asthma for Optimal DIsease management (RAPSODI). Patients that started with anti-IL-5/5Ra biologics and completed the work productivity and activity improvement questionnaire, were included. Study and patient characteristics were compared between the employed and unemployed patients. Work productivity and activity impairment are related to accompanying improvements in clinical outcomes.
At baseline, 91 of 137 patients (66%) were employed which remained stable throughout the follow-up period. Patients in the working age category were younger and had significantly better asthma control ( = 0.02). Mean overall work impairment due to health decreased significantly from 25.5% (SD2.6) to 17.6% (SD 2.8) during 12 months anti-IL-5/5Ra biologics treatment ( = 0.010). There was a significant association between ACQ6 and overall work improvement after targeted therapy (β = 8.7, CI 2.1-15.4, = 0.01). The improvement of asthma control of 0.5 points on the asthma Control Questionnaire was associated with an overall work impairment of -9%.
Work productivity and activity in severe eosinophilic asthma improved after starting anti-IL-5/5Ra biologics. Clinically relevant improvement in asthma control was associated with an overall work impairment score of -9% in this study.
重度哮喘与严重的疾病负担有关，部分原因是活动受限和工作能力受损。
本研究旨在从现实角度研究针对白细胞介素-5/5Ra 的生物制剂治疗与长期工作生产力和活动之间的关系。
这是一项基于登记的多中心队列研究，评估了荷兰成人严重哮喘登记处纳入的重度嗜酸性粒细胞性哮喘成年患者（RAPSODI）的数据。纳入开始使用抗白细胞介素-5/5Ra 生物制剂且完成工作生产力和活动改善问卷的患者。比较了就业和失业患者的研究和患者特征。工作生产力和活动受损与伴随的临床结果改善相关。
在基线时，137 名患者中有 91 名（66%）就业，这一比例在整个随访期间保持稳定。处于工作年龄段的患者更年轻，哮喘控制明显更好（ = 0.02）。使用抗白细胞介素-5/5Ra 生物制剂治疗 12 个月后，整体健康相关工作受损的平均比例从 25.5%（SD2.6）显著下降至 17.6%（SD 2.8）（ = 0.010）。在靶向治疗后，ACQ6 与整体工作改善之间存在显著相关性（β = 8.7，CI 2.1-15.4， = 0.01）。哮喘控制问卷上哮喘控制改善 0.5 分与整体工作受损 9%相关。
开始使用抗白细胞介素-5/5Ra 生物制剂后，重度嗜酸性粒细胞性哮喘患者的工作生产力和活动得到改善。在这项研究中，临床相关的哮喘控制改善与整体工作受损评分-9%相关。
